Shares of Novartis AG (NYSE:NVS) have been assigned an average recommendation of “Hold” from the eighteen research firms that are currently covering the stock. Three research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $92.75.
Several research firms have weighed in on NVS. Zacks Investment Research upgraded Novartis AG from a “hold” rating to a “buy” rating and set a $92.00 target price on the stock in a report on Monday, July 11th. JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis AG in a report on Tuesday, September 13th. TheStreet upgraded Novartis AG from a “hold” rating to a “buy” rating in a report on Friday, June 24th. Chardan Capital cut their target price on Novartis AG from $95.00 to $92.00 and set a “buy” rating on the stock in a report on Monday, October 10th. Finally, Bank of America Corp. restated a “hold” rating on shares of Novartis AG in a report on Tuesday, July 12th.
Novartis AG (NYSE:NVS) opened at 76.09 on Wednesday. The company has a market cap of $181.19 billion, a P/E ratio of 27.17 and a beta of 0.57. Novartis AG has a 12-month low of $69.90 and a 12-month high of $94.63. The firm’s 50-day moving average price is $79.33 and its 200-day moving average price is $78.96.
Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.05. Novartis AG had a return on equity of 15.33% and a net margin of 13.84%. The company had revenue of $12.47 billion for the quarter, compared to analyst estimates of $12.33 billion. During the same period last year, the company earned $1.25 earnings per share. Analysts expect that Novartis AG will post $4.72 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in NVS. Integrated Investment Consultants LLC increased its stake in Novartis AG by 6.3% in the second quarter. Integrated Investment Consultants LLC now owns 1,240 shares of the company’s stock worth $102,000 after buying an additional 74 shares during the period. Whitnell & Co. increased its stake in Novartis AG by 14.6% in the second quarter. Whitnell & Co. now owns 1,410 shares of the company’s stock worth $116,000 after buying an additional 180 shares during the last quarter. Iowa State Bank bought a new stake in Novartis AG during the second quarter worth $122,000. M&R Capital Management Inc. bought a new stake in Novartis AG during the second quarter worth $122,000. Finally, WFG Advisors LP increased its stake in Novartis AG by 8.9% in the second quarter. WFG Advisors LP now owns 1,624 shares of the company’s stock worth $134,000 after buying an additional 133 shares during the last quarter. 9.77% of the stock is currently owned by institutional investors and hedge funds.
Novartis AG Company Profile
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.